CEFADROXIL

Product NDC: 63304-974
11-digit product format: 633040974
Labeler code: 63304
Product ID: 63304-974_a95b07d7-65c1-438d-91e0-0eaca684eccf
Type: HUMAN PRESCRIPTION DRUG
Nonproprietary name: cefadroxil monohydrate
Dosage form: POWDER, FOR SUSPENSION
Route: ORAL
Labeler: Ranbaxy Pharmaceuticals Inc.
Application: ANDA065115
Marketing category: ANDA
Marketing start: 2005-08-30
Marketing end: 0000-00-00
Substance: CEFADROXIL
Active strength: 500 mg/5mL
Pharmacologic classes: Cephalosporin Antibacterial [EPC],Cephalosporins [CS]
NDC exclude flag: E
Listing certified through: 2017-12-31
Current FDA listing: Historical FDA.report record

NDC auxiliary status#

These records are reproduced from FDA’s unfinished, excluded, and compounder listings. They describe what appeared in the source files; a missing record does not establish a regulatory status. View all current auxiliary records, including entries without an NDC. · View the auxiliary file history.

Current NDC status page 1 of 1 · 3 matching rows.

Dataset, Scope, Product NDC table
Dataset	Scope	Product NDC	Package NDC	Code	Status	Source date
excluded product	product	63304-974		I	Inactivated by FDA	2026-08-17
excluded package	package	63304-974	63304-974-01	I	Inactivated by FDA	2026-08-17
excluded package	package	63304-974	63304-974-04	I	Inactivated by FDA	2026-08-17

Observed NDC auxiliary status history#

This history shows the information present in each captured FDA auxiliary file. It is not a continuous regulatory timeline, and a missing record does not establish a status.

Historic NDC status page 1 of 2 · 66 matching rows.

View current auxiliary records. · View the auxiliary file history.

Captured / source date, Dataset, Scope table
Captured / source date	Dataset	Scope	Package NDC	Snapshot	Source SHA-256
2025-12-14 17:58 UTC · source 2025-12-05	excluded product	product		`d630ba8d3edf…`	`732f749b63fb…`
2025-12-14 17:58 UTC · source 2025-12-05	excluded package	package	63304-974-04	`d630ba8d3edf…`	`732f749b63fb…`
2025-12-14 17:58 UTC · source 2025-12-05	excluded package	package	63304-974-01	`d630ba8d3edf…`	`732f749b63fb…`
2025-08-27 00:01 UTC · source 2025-08-26	excluded product	product		`f5e01cc5f278…`	`a2eaf40c39c3…`
2025-08-27 00:01 UTC · source 2025-08-26	excluded package	package	63304-974-04	`f5e01cc5f278…`	`a2eaf40c39c3…`
2025-08-27 00:01 UTC · source 2025-08-26	excluded package	package	63304-974-01	`f5e01cc5f278…`	`a2eaf40c39c3…`
2025-04-01 02:39 UTC · source 2025-03-31	excluded product	product		`2ef7874e63bc…`	`57b86245f4fa…`
2025-04-01 02:39 UTC · source 2025-03-31	excluded package	package	63304-974-04	`2ef7874e63bc…`	`57b86245f4fa…`
2025-04-01 02:39 UTC · source 2025-03-31	excluded package	package	63304-974-01	`2ef7874e63bc…`	`57b86245f4fa…`
2025-03-28 20:22 UTC · source 2025-03-28	excluded product	product		`a1b67e2a42f9…`	`c4cf2c586c0d…`
2025-03-28 20:22 UTC · source 2025-03-28	excluded package	package	63304-974-04	`a1b67e2a42f9…`	`c4cf2c586c0d…`
2025-03-28 20:22 UTC · source 2025-03-28	excluded package	package	63304-974-01	`a1b67e2a42f9…`	`c4cf2c586c0d…`
2025-03-22 03:12 UTC · source 2025-03-21	excluded product	product		`cfe11265f3b6…`	`090c488252e2…`
2025-03-22 03:12 UTC · source 2025-03-21	excluded package	package	63304-974-04	`cfe11265f3b6…`	`090c488252e2…`
2025-03-22 03:12 UTC · source 2025-03-21	excluded package	package	63304-974-01	`cfe11265f3b6…`	`090c488252e2…`
2025-03-10 12:48 UTC · source 2025-03-10	excluded product	product		`cdf11ea48f46…`	`ba0047e9e063…`
2025-03-10 12:48 UTC · source 2025-03-10	excluded package	package	63304-974-04	`cdf11ea48f46…`	`ba0047e9e063…`
2025-03-10 12:48 UTC · source 2025-03-10	excluded package	package	63304-974-01	`cdf11ea48f46…`	`ba0047e9e063…`
2025-02-02 03:52 UTC · source 2025-01-31	excluded product	product		`302b2466d912…`	`e7b80fea0513…`
2025-02-02 03:52 UTC · source 2025-01-31	excluded package	package	63304-974-04	`302b2466d912…`	`e7b80fea0513…`
2025-02-02 03:52 UTC · source 2025-01-31	excluded package	package	63304-974-01	`302b2466d912…`	`e7b80fea0513…`
2025-01-20 13:05 UTC · source 2025-01-20	excluded product	product		`ed331223b511…`	`672a5bd82f5f…`
2025-01-20 13:05 UTC · source 2025-01-20	excluded package	package	63304-974-04	`ed331223b511…`	`672a5bd82f5f…`
2025-01-20 13:05 UTC · source 2025-01-20	excluded package	package	63304-974-01	`ed331223b511…`	`672a5bd82f5f…`
2025-01-11 03:41 UTC · source 2025-01-10	excluded product	product		`0efc9e666f02…`	`f202fb6c5f17…`
2025-01-11 03:41 UTC · source 2025-01-10	excluded package	package	63304-974-04	`0efc9e666f02…`	`f202fb6c5f17…`
2025-01-11 03:41 UTC · source 2025-01-10	excluded package	package	63304-974-01	`0efc9e666f02…`	`f202fb6c5f17…`
2024-11-09 02:27 UTC · source 2024-11-08	excluded product	product		`ad56d346431e…`	`cc804d4bbf1e…`
2024-11-09 02:27 UTC · source 2024-11-08	excluded package	package	63304-974-04	`ad56d346431e…`	`cc804d4bbf1e…`
2024-11-09 02:27 UTC · source 2024-11-08	excluded package	package	63304-974-01	`ad56d346431e…`	`cc804d4bbf1e…`
2024-10-04 04:10 UTC · source 2024-10-03	excluded product	product		`367a005e9d99…`	`383a685ebd0f…`
2024-10-04 04:10 UTC · source 2024-10-03	excluded package	package	63304-974-04	`367a005e9d99…`	`383a685ebd0f…`
2024-10-04 04:10 UTC · source 2024-10-03	excluded package	package	63304-974-01	`367a005e9d99…`	`383a685ebd0f…`
2024-07-10 04:00 UTC · source 2024-07-09	excluded product	product		`557ba5c1ecfa…`	`9c80585c8c6e…`
2024-07-10 04:00 UTC · source 2024-07-09	excluded package	package	63304-974-04	`557ba5c1ecfa…`	`9c80585c8c6e…`
2024-07-10 04:00 UTC · source 2024-07-09	excluded package	package	63304-974-01	`557ba5c1ecfa…`	`9c80585c8c6e…`
2024-05-28 21:12 UTC · source 2024-05-28	excluded product	product		`8af77b9d5b6f…`	`d9bbb34c5368…`
2024-05-28 21:12 UTC · source 2024-05-28	excluded package	package	63304-974-04	`8af77b9d5b6f…`	`d9bbb34c5368…`
2024-05-28 21:12 UTC · source 2024-05-28	excluded package	package	63304-974-01	`8af77b9d5b6f…`	`d9bbb34c5368…`
2024-05-15 03:39 UTC · source 2024-05-14	excluded product	product		`834df4deac94…`	`adcc014656a3…`
2024-05-15 03:39 UTC · source 2024-05-14	excluded package	package	63304-974-04	`834df4deac94…`	`adcc014656a3…`
2024-05-15 03:39 UTC · source 2024-05-14	excluded package	package	63304-974-01	`834df4deac94…`	`adcc014656a3…`
2024-03-11 06:39 UTC · source 2024-03-08	excluded product	product		`1332a3947898…`	`d4bfe170f9cd…`
2024-03-11 06:39 UTC · source 2024-03-08	excluded package	package	63304-974-04	`1332a3947898…`	`d4bfe170f9cd…`
2024-03-11 06:39 UTC · source 2024-03-08	excluded package	package	63304-974-01	`1332a3947898…`	`d4bfe170f9cd…`
2022-08-30 03:57 UTC · source 2022-08-29	excluded product	product		`fb8cb913e6d1…`	`eb8c232b6be0…`
2022-08-30 03:57 UTC · source 2022-08-29	excluded package	package	63304-974-04	`fb8cb913e6d1…`	`eb8c232b6be0…`
2022-08-30 03:57 UTC · source 2022-08-29	excluded package	package	63304-974-01	`fb8cb913e6d1…`	`eb8c232b6be0…`
2022-04-09 23:13 UTC · source 2022-04-08	excluded product	product		`86f5da6cb304…`	`a595104c45d7…`
2022-04-09 23:13 UTC · source 2022-04-08	excluded package	package	63304-974-04	`86f5da6cb304…`	`a595104c45d7…`
2022-04-09 23:13 UTC · source 2022-04-08	excluded package	package	63304-974-01	`86f5da6cb304…`	`a595104c45d7…`
2022-04-04 05:40 UTC · source 2022-04-01	excluded product	product		`bd6a592717d7…`	`303034d00443…`
2022-04-04 05:40 UTC · source 2022-04-01	excluded package	package	63304-974-04	`bd6a592717d7…`	`303034d00443…`
2022-04-04 05:40 UTC · source 2022-04-01	excluded package	package	63304-974-01	`bd6a592717d7…`	`303034d00443…`
2021-12-27 23:28 UTC · source 2021-12-27	excluded product	product		`8dfbde2a14a4…`	`c9ff85d89658…`
2021-12-27 23:28 UTC · source 2021-12-27	excluded package	package	63304-974-04	`8dfbde2a14a4…`	`c9ff85d89658…`
2021-12-27 23:28 UTC · source 2021-12-27	excluded package	package	63304-974-01	`8dfbde2a14a4…`	`c9ff85d89658…`
2020-12-18 03:04 UTC · source 2020-12-17	excluded product	product		`e2bbac7714bc…`	`27bdfed8d636…`
2020-12-18 03:04 UTC · source 2020-12-17	excluded package	package	63304-974-04	`e2bbac7714bc…`	`27bdfed8d636…`
2020-12-18 03:04 UTC · source 2020-12-17	excluded package	package	63304-974-01	`e2bbac7714bc…`	`27bdfed8d636…`

Source provenance: Browse the complete Orange Book source catalog · source snapshot 42.

Orange Book products#

Current product rows page 1 of 1 · 3 matching rows.

Application-product, Trade name, Ingredient table
Application-product	Trade name	Ingredient	Strength	Dosage form / route	Approval date
A065115-001	CEFADROXIL	CEFADROXIL/CEFADROXIL HEMIHYDRATE	EQ 125MG BASE/5ML	FOR SUSPENSION / ORAL	2003-03-26
A065115-002	CEFADROXIL	CEFADROXIL/CEFADROXIL HEMIHYDRATE	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL	2003-03-26
A065115-003	CEFADROXIL	CEFADROXIL/CEFADROXIL HEMIHYDRATE	EQ 500MG BASE/5ML	FOR SUSPENSION / ORAL	2003-03-26

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 4 · 126 observed states.

Captured, Edition, Application-product table
Captured	Edition	Application-product	Trade name	Strength	Dosage form / route	Approval date	Source SHA-256
2026-08-18 06:07:40	2026-07	A065115-001	CEFADROXIL	EQ 125MG BASE/5ML	FOR SUSPENSION / ORAL	2003-03-26	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	A065115-002	CEFADROXIL	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL	2003-03-26	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	A065115-003	CEFADROXIL	EQ 500MG BASE/5ML	FOR SUSPENSION / ORAL	2003-03-26	`caaa826d4ba7…`
2026-02-19 14:30 UTC	2026-02	A065115-001	CEFADROXIL	EQ 125MG BASE/5ML	FOR SUSPENSION / ORAL	2003-03-26	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	A065115-002	CEFADROXIL	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL	2003-03-26	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	A065115-003	CEFADROXIL	EQ 500MG BASE/5ML	FOR SUSPENSION / ORAL	2003-03-26	`011fe1cb6892…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	A065115-001	CEFADROXIL	EQ 125MG BASE/5ML	FOR SUSPENSION / ORAL	2003-03-26	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	A065115-002	CEFADROXIL	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL	2003-03-26	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	A065115-003	CEFADROXIL	EQ 500MG BASE/5ML	FOR SUSPENSION / ORAL	2003-03-26	`31067a03dcf5…`
2025-08-23 18:47 UTC	2025-08	A065115-001	CEFADROXIL	EQ 125MG BASE/5ML	FOR SUSPENSION / ORAL	2003-03-26	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	A065115-002	CEFADROXIL	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL	2003-03-26	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	A065115-003	CEFADROXIL	EQ 500MG BASE/5ML	FOR SUSPENSION / ORAL	2003-03-26	`6a471c1ec25d…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	A065115-001	CEFADROXIL	EQ 125MG BASE/5ML	FOR SUSPENSION / ORAL	2003-03-26	`fd3edfee7708…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	A065115-002	CEFADROXIL	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL	2003-03-26	`fd3edfee7708…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	A065115-003	CEFADROXIL	EQ 500MG BASE/5ML	FOR SUSPENSION / ORAL	2003-03-26	`fd3edfee7708…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	A065115-001	CEFADROXIL	EQ 125MG BASE/5ML	FOR SUSPENSION / ORAL	2003-03-26	`b8a1b40f171c…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	A065115-002	CEFADROXIL	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL	2003-03-26	`b8a1b40f171c…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	A065115-003	CEFADROXIL	EQ 500MG BASE/5ML	FOR SUSPENSION / ORAL	2003-03-26	`b8a1b40f171c…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	A065115-001	CEFADROXIL	EQ 125MG BASE/5ML	FOR SUSPENSION / ORAL	2003-03-26	`03ed91905a0d…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	A065115-002	CEFADROXIL	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL	2003-03-26	`03ed91905a0d…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	A065115-003	CEFADROXIL	EQ 500MG BASE/5ML	FOR SUSPENSION / ORAL	2003-03-26	`03ed91905a0d…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	A065115-001	CEFADROXIL	EQ 125MG BASE/5ML	FOR SUSPENSION / ORAL	2003-03-26	`2680178bc6a6…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	A065115-002	CEFADROXIL	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL	2003-03-26	`2680178bc6a6…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	A065115-003	CEFADROXIL	EQ 500MG BASE/5ML	FOR SUSPENSION / ORAL	2003-03-26	`2680178bc6a6…`
2024-09-14 05:58 UTC · 2 captures of this ZIP	2024-09	A065115-001	CEFADROXIL	EQ 125MG BASE/5ML	FOR SUSPENSION / ORAL	2003-03-26	`5bbf6a4d5a75…`
2024-09-14 05:58 UTC · 2 captures of this ZIP	2024-09	A065115-002	CEFADROXIL	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL	2003-03-26	`5bbf6a4d5a75…`
2024-09-14 05:58 UTC · 2 captures of this ZIP	2024-09	A065115-003	CEFADROXIL	EQ 500MG BASE/5ML	FOR SUSPENSION / ORAL	2003-03-26	`5bbf6a4d5a75…`
2024-11-08 22:44 UTC · 3 captures of this ZIP	2024-11	A065115-001	CEFADROXIL	EQ 125MG BASE/5ML	FOR SUSPENSION / ORAL	2003-03-26	`d8e5a09893c0…`
2024-11-08 22:44 UTC · 3 captures of this ZIP	2024-11	A065115-002	CEFADROXIL	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL	2003-03-26	`d8e5a09893c0…`
2024-11-08 22:44 UTC · 3 captures of this ZIP	2024-11	A065115-003	CEFADROXIL	EQ 500MG BASE/5ML	FOR SUSPENSION / ORAL	2003-03-26	`d8e5a09893c0…`
2024-10-29 15:01 UTC	2024-10	A065115-001	CEFADROXIL	EQ 125MG BASE/5ML	FOR SUSPENSION / ORAL	2003-03-26	`d06236e962d9…`
2024-10-29 15:01 UTC	2024-10	A065115-002	CEFADROXIL	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL	2003-03-26	`d06236e962d9…`
2024-10-29 15:01 UTC	2024-10	A065115-003	CEFADROXIL	EQ 500MG BASE/5ML	FOR SUSPENSION / ORAL	2003-03-26	`d06236e962d9…`
2024-08-13 05:28 UTC · 3 captures of this ZIP	2024-08	A065115-001	CEFADROXIL	EQ 125MG BASE/5ML	FOR SUSPENSION / ORAL	2003-03-26	`79d66fd596c7…`
2024-08-13 05:28 UTC · 3 captures of this ZIP	2024-08	A065115-002	CEFADROXIL	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL	2003-03-26	`79d66fd596c7…`
2024-08-13 05:28 UTC · 3 captures of this ZIP	2024-08	A065115-003	CEFADROXIL	EQ 500MG BASE/5ML	FOR SUSPENSION / ORAL	2003-03-26	`79d66fd596c7…`
2024-07-13 05:37 UTC · 2 captures of this ZIP	2024-07	A065115-001	CEFADROXIL	EQ 125MG BASE/5ML	FOR SUSPENSION / ORAL	2003-03-26	`301d65b070ca…`
2024-07-13 05:37 UTC · 2 captures of this ZIP	2024-07	A065115-002	CEFADROXIL	EQ 250MG BASE/5ML	FOR SUSPENSION / ORAL	2003-03-26	`301d65b070ca…`
2024-07-13 05:37 UTC · 2 captures of this ZIP	2024-07	A065115-003	CEFADROXIL	EQ 500MG BASE/5ML	FOR SUSPENSION / ORAL	2003-03-26	`301d65b070ca…`
2024-06-18 03:08 UTC · 5 captures of this ZIP	2024-06	A065115-001	CEFADROXIL	EQ 125MG BASE/5ML	FOR SUSPENSION / ORAL	2003-03-26	`1e350fbaab3a…`

DailyMed Product Concepts#

Product concept, Relation, Version table
Product concept	Relation	Version	Effective
560bed03-0257-a1db-0638-2c46fc35054c	Product name	2	20170824
34f1b9ee-0673-df8c-ddae-36eaf4c48382	Product name	1	20140508
3793572a-4958-68b2-f923-8cf695ec1cc1	Product name	1	20140508

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDC	Effective	Action	Document	Indexing SPL	Related label
63304-974-01	2019-11-27	C162847	48780-1	9855d018-d2a7-cd31-e053-dbdaa90ab51a	CEFADROXIL FOR ORAL SUSPENSION, USP Rx only
63304-974-04	2019-11-27	C162847	48780-1	9855d018-d2a7-cd31-e053-dbdaa90ab51a	CEFADROXIL FOR ORAL SUSPENSION, USP Rx only

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDC	Product	Description	Form	Quantity	Strength	SPL version
63304-974-01	CEFADROXIL	75 mL in 1 BOTTLE	POWDER, FOR SUSPENSION	75		2
63304-974-04	CEFADROXIL	100 mL in 1 BOTTLE	POWDER, FOR SUSPENSION	100		2

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDC	Billing unit	Product NDC	DailyMed indexing SPL	SPL version	Effective
63304-974-01	ML - Milliliter	63304-974	e187cda9-4fb4-4516-bc0f-8f09dc215240	1	2013-02-13
63304-974-04	ML - Milliliter	63304-974	6d30c130-0ac2-4735-8fc2-c01e9217b7dd	1	2013-02-13

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
Ingredient	Type	UNII	DailyMed label	SPL version
CEFADROXIL	ACTIVE INGREDIENT	280111G160	CEFADROXIL (CEFADROXIL MONOHYDRATE) POWDER, FOR SUSPENSION [RANBAXY PHARMACEUTICALS INC.]	2
CEFADROXIL ANHYDROUS	ACTIVE MOIETY	Q525PA8JJB	CEFADROXIL (CEFADROXIL MONOHYDRATE) POWDER, FOR SUSPENSION [RANBAXY PHARMACEUTICALS INC.]	2
FD&C YELLOW NO. 6	INACTIVE INGREDIENT	H77VEI93A8	CEFADROXIL (CEFADROXIL MONOHYDRATE) POWDER, FOR SUSPENSION [RANBAXY PHARMACEUTICALS INC.]	2
FRUIT	INACTIVE INGREDIENT	C2AIY4ERZC	CEFADROXIL (CEFADROXIL MONOHYDRATE) POWDER, FOR SUSPENSION [RANBAXY PHARMACEUTICALS INC.]	2
POLYSORBATE 80	INACTIVE INGREDIENT	6OZP39ZG8H	CEFADROXIL (CEFADROXIL MONOHYDRATE) POWDER, FOR SUSPENSION [RANBAXY PHARMACEUTICALS INC.]	2
RASPBERRY	INACTIVE INGREDIENT	4N14V5R27W	CEFADROXIL (CEFADROXIL MONOHYDRATE) POWDER, FOR SUSPENSION [RANBAXY PHARMACEUTICALS INC.]	2
SILICON DIOXIDE	INACTIVE INGREDIENT	ETJ7Z6XBU4	CEFADROXIL (CEFADROXIL MONOHYDRATE) POWDER, FOR SUSPENSION [RANBAXY PHARMACEUTICALS INC.]	2
SODIUM BENZOATE	INACTIVE INGREDIENT	OJ245FE5EU	CEFADROXIL (CEFADROXIL MONOHYDRATE) POWDER, FOR SUSPENSION [RANBAXY PHARMACEUTICALS INC.]	2
SUCROSE	INACTIVE INGREDIENT	C151H8M554	CEFADROXIL (CEFADROXIL MONOHYDRATE) POWDER, FOR SUSPENSION [RANBAXY PHARMACEUTICALS INC.]	2
XANTHAN GUM	INACTIVE INGREDIENT	TTV12P4NEE	CEFADROXIL (CEFADROXIL MONOHYDRATE) POWDER, FOR SUSPENSION [RANBAXY PHARMACEUTICALS INC.]	2
CEFADROXIL	ACTIVE INGREDIENT	280111G160	CEFADROXIL (CEFADROXIL MONOHYDRATE) POWDER, FOR SUSPENSION [PHYSICIANS TOTAL CARE, INC.]	1
CEFADROXIL	ACTIVE MOIETY	280111G160	CEFADROXIL (CEFADROXIL MONOHYDRATE) POWDER, FOR SUSPENSION [PHYSICIANS TOTAL CARE, INC.]	1
FD&C YELLOW NO. 6	INACTIVE INGREDIENT	H77VEI93A8	CEFADROXIL (CEFADROXIL MONOHYDRATE) POWDER, FOR SUSPENSION [PHYSICIANS TOTAL CARE, INC.]	1
POLYSORBATE 80	INACTIVE INGREDIENT	6OZP39ZG8H	CEFADROXIL (CEFADROXIL MONOHYDRATE) POWDER, FOR SUSPENSION [PHYSICIANS TOTAL CARE, INC.]	1
SILICON DIOXIDE	INACTIVE INGREDIENT	ETJ7Z6XBU4	CEFADROXIL (CEFADROXIL MONOHYDRATE) POWDER, FOR SUSPENSION [PHYSICIANS TOTAL CARE, INC.]	1
SODIUM BENZOATE	INACTIVE INGREDIENT	OJ245FE5EU	CEFADROXIL (CEFADROXIL MONOHYDRATE) POWDER, FOR SUSPENSION [PHYSICIANS TOTAL CARE, INC.]	1
SUCROSE	INACTIVE INGREDIENT	C151H8M554	CEFADROXIL (CEFADROXIL MONOHYDRATE) POWDER, FOR SUSPENSION [PHYSICIANS TOTAL CARE, INC.]	1
XANTHAN GUM	INACTIVE INGREDIENT	TTV12P4NEE	CEFADROXIL (CEFADROXIL MONOHYDRATE) POWDER, FOR SUSPENSION [PHYSICIANS TOTAL CARE, INC.]	1

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDC	Dashboard title	SPL version	Validation	Dashboard ZIP
63304-974	CEFADROXIL (CEFADROXIL MONOHYDRATE) POWDER, FOR SUSPENSION [RANBAXY PHARMACEUTICALS INC.]	2	Legacy NDC, 2 package rows	20130321_5fc4f89c-cf94-4e7a-bf31-d3d86a242efa.zip

UNII, Preferred term, Registry number table
UNII	Preferred term	Registry number	Matched term
280111G160	CEFADROXIL	66592-87-8	CEFADROXIL

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUI	RxNorm string	TTY	DailyMed	SPL version
309048	cefadroxil 250 MG in 5 mL Oral Suspension	PSN	5fc4f89c-cf94-4e7a-bf31-d3d86a242efa	2
105171	cefadroxil 500 MG in 5 mL Oral Suspension	PSN	5fc4f89c-cf94-4e7a-bf31-d3d86a242efa	2
105171	cefadroxil 100 MG/ML Oral Suspension	SCD	5fc4f89c-cf94-4e7a-bf31-d3d86a242efa	2
105170	cefadroxil 25 MG/ML Oral Suspension	SCD	5fc4f89c-cf94-4e7a-bf31-d3d86a242efa	2
309048	cefadroxil 50 MG/ML Oral Suspension	SCD	5fc4f89c-cf94-4e7a-bf31-d3d86a242efa	2
105171	cefadroxil (as cefadroxil monohydrate) 100 MG/ML Oral Suspension	SY	5fc4f89c-cf94-4e7a-bf31-d3d86a242efa	2
105170	cefadroxil (as cefadroxil monohydrate) 25 MG/ML Oral Suspension	SY	5fc4f89c-cf94-4e7a-bf31-d3d86a242efa	2
309048	cefadroxil (as cefadroxil monohydrate) 50 MG/ML Oral Suspension	SY	5fc4f89c-cf94-4e7a-bf31-d3d86a242efa	2
105170	cefadroxil 125 MG per 5 ML Oral Suspension	SY	5fc4f89c-cf94-4e7a-bf31-d3d86a242efa	2
309048	cefadroxil 250 MG per 5 ML Powder for Oral Suspension	SY	5fc4f89c-cf94-4e7a-bf31-d3d86a242efa	2
105171	cefadroxil 500 MG per 5 ML Powder for Oral Suspension	SY	5fc4f89c-cf94-4e7a-bf31-d3d86a242efa	2
309048	cefadroxil 250 MG in 5 mL Oral Suspension	PSN	4306730b-e894-45ca-b4e9-3fe7f65b7b1d	1
105171	cefadroxil 500 MG in 5 mL Oral Suspension	PSN	4306730b-e894-45ca-b4e9-3fe7f65b7b1d	1
105171	cefadroxil 100 MG/ML Oral Suspension	SCD	4306730b-e894-45ca-b4e9-3fe7f65b7b1d	1
309048	cefadroxil 50 MG/ML Oral Suspension	SCD	4306730b-e894-45ca-b4e9-3fe7f65b7b1d	1
105171	cefadroxil (as cefadroxil monohydrate) 100 MG/ML Oral Suspension	SY	4306730b-e894-45ca-b4e9-3fe7f65b7b1d	1
309048	cefadroxil (as cefadroxil monohydrate) 50 MG/ML Oral Suspension	SY	4306730b-e894-45ca-b4e9-3fe7f65b7b1d	1
309048	cefadroxil 250 MG per 5 ML Powder for Oral Suspension	SY	4306730b-e894-45ca-b4e9-3fe7f65b7b1d	1
105171	cefadroxil 500 MG per 5 ML Powder for Oral Suspension	SY	4306730b-e894-45ca-b4e9-3fe7f65b7b1d	1

Packages#

Package NDC, 11-digit format, Description table
Package NDC	11-digit format	Description	Units	Status
63304-974-01	63304097401	75 mL in 1 BOTTLE	75 ml	Historical
63304-974-04	63304097404	100 mL in 1 BOTTLE	100 ml	Historical

Title, Manufacturer, Effective date table
Title	Manufacturer	Effective date	Type	Version
CEFADROXIL FOR ORAL SUSPENSION, USP Rx only	Ranbaxy Pharmaceuticals Inc. \| RANBAXY LABORATORIES LIMITED - DEWAS	2013-08-14	HUMAN PRESCRIPTION DRUG LABEL	2
Cefadroxil - Physicians Total Care, Inc.	Physicians Total Care, Inc.	2010-05-11	HUMAN PRESCRIPTION DRUG LABEL	1